ArticlePloS one2025
Combination of modified albumin-bilirubin grade and platelet count to predict high-risk varices in patients with hepatocellular carcinoma.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVariceal bleeding is associated with poor prognosis in patients with hepatocellular carcinoma. Therefore, it is essential to identify indicators of high-risk varices (HRV) and provide prompt intervention.
aimTo validate and modify albumin-bilirubin and platelet scores to predict high-risk varices in patients with hepatocellular carcinoma.
methodsWe enrolled patients with hepatocellular carcinoma and esophagogastroduodenoscopy reports at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, between 2015 and 2022. The nearest demographic and clinical characteristics and laboratory values were reviewed retrospectively within 6 months before the esophagogastroduodenoscopy. Albumin-bilirubin and platelet counts were calculated from the albumin-bilirubin grade plus score from platelet count. We evaluated the new modified albumin-bilirubin and platelet (mALBI-PLT)'s in predicting HRV by dividing participants into a training cohort (first half) and a validation cohort (second half).
resultsOf 564 patients with hepatocellular carcinoma, 277 were included. Most patients (232 [83.8%]) had Child-Turcotte-Pugh A cirrhosis, whereas 131 (47.3%), 85 (30.7%), and 60 (22.0%) had Barcelona Clinic Liver Cancer stages A, B, and C, respectively. Thirty-eight (15.6%) participants had HRV on esophagogastroduodenoscopy. On multivariate analysis, modified albumin-bilirubin grades 2b and 3 and platelet count ≤150,000/µL were significantly associated with HRV. With a cut-off value of 2, the mALBI-PLT showed comparable performance in both cohorts, yielding sensitivities of 93.8% and 95.5%, and negative predictive values (NPV) of 98.1% and 98.0%, respectively. In the entire cohort, the albumin-bilirubin and platelet scores, and mALBI-PLT score >2, demonstrated excellent sensitivities (97.4% and 94.7%), respectively, (with NPV of 98.7% and 98.0%), in predicting HRV.
conclusionModified albumin-bilirubin grade and platelet at cut-off 150,000/µL exhibited significant association with high-risk varices in patients with hepatocellular carcinoma. Moreover, hepatocellular carcinoma patients with modified albumin-bilirubin grade 1 or 2a, together with platelets > 150,000/µL, may be able to avoid oesophagogastroduodenoscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.